Trial | NCT04451239  Report issue

Title

Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis
Combined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis; a Pilot Study

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    12
To explore the feasibility of combined topical corticosteroid and topical cyclosporine-A in COVID-19 patients with acute keratoconjunctivitis.
COVID-19 patients presenting with acute keratoconjunctivitis will be treated with Topical 1% prednisolone acetate fourTimes daily for 7 days as initial treatment, non-preserved artificial tears four times daily and cyclosporin A 0.5% four times daily .

Twelve patients with COVID-19 Keratoconjunctivitis will be enrolled in this open-label study. Symptoms and findings of the patients before and after treatment were recorded.
Study Started
Jun 30
2020
Anticipated
Primary Completion
Jul 31
2020
Anticipated
Study Completion
Jul 31
2020
Anticipated
Last Update
Jun 30
2020

Drug topical steroids and cyclosporin-A [prednisolone (hydeltra), cyclosporine (sandimmune)]

All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .

COVID-19 keratoconjunctivitis Other

cases will receive topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .

Criteria 

Inclusion Criteria:

COVID-19 Patients with keratoconjunctivitis

Exclusion Criteria:

associated ocular pathology or disease
other causes of keratoconjunctivitis for example allergic or herpetic
No Results Posted